- Home
- EWTX vs CSR Comparison
EWTX vs CSR Comparison
Compare EWTX & CSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- CSR
- Stock Information
- Founded
- EWTX 2017
- CSR 1970
- Country
- EWTX United States
- CSR United States
- Employees
- EWTX N/A
- CSR N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- CSR Real Estate Investment Trusts
- Sector
- EWTX Health Care
- CSR Real Estate
- Exchange
- EWTX Nasdaq
- CSR Nasdaq
- Market Cap
- EWTX 1.2B
- CSR 1.0B
- IPO Year
- EWTX 2021
- CSR N/A
- Fundamental
- Price
- EWTX $14.28
- CSR $63.78
- Analyst Decision
- EWTX Buy
- CSR Buy
- Analyst Count
- EWTX 8
- CSR 8
- Target Price
- EWTX $40.13
- CSR $72.13
- AVG Volume (30 Days)
- EWTX 1.1M
- CSR 103.8K
- Earning Date
- EWTX 05-08-2025
- CSR 07-28-2025
- Dividend Yield
- EWTX N/A
- CSR 4.83%
- EPS Growth
- EWTX N/A
- CSR N/A
- EPS
- EWTX N/A
- CSR N/A
- Revenue
- EWTX N/A
- CSR $263,570,000.00
- Revenue This Year
- EWTX N/A
- CSR $4.42
- Revenue Next Year
- EWTX N/A
- CSR $3.42
- P/E Ratio
- EWTX N/A
- CSR N/A
- Revenue Growth
- EWTX N/A
- CSR 2.19
- 52 Week Low
- EWTX $10.60
- CSR $54.13
- 52 Week High
- EWTX $38.12
- CSR $76.16
- Technical
- Relative Strength Index (RSI)
- EWTX 43.22
- CSR 59.72
- Support Level
- EWTX $13.80
- CSR $60.91
- Resistance Level
- EWTX $14.68
- CSR $64.10
- Average True Range (ATR)
- EWTX 0.78
- CSR 1.96
- MACD
- EWTX 0.08
- CSR 0.15
- Stochastic Oscillator
- EWTX 29.68
- CSR 86.39
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.